The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Recent ELCC data released by J&J proves that the expanded adverse reactions seen during phase III trials of Mariposa can be managed. With approval expected mid-year, now is the time to pay attention
It has been revealed that nine out of the top 10 major corporations have seen unanimous approval from external directors on board resolutions.Corporate data research institute CEO Score announced on March 13 that out of the 181 companies listed among the top 500 domestic companies by revenue, which
The author is an analyst for NH Investment & Securities. He can be reached at bk@nhqv.com -- Ed.Global stock markets have rallied of late, with the S&P500 surging for four months in a row. In February, the Kospi has outperformed other major markets. But, the fast market growth is likely to bolster p
The author is an analyst for NH Investment & Securities. He can be reached at bk@nhqv.com -- Ed.The two terms that defined last year’s stock market were ‘new cold war’ and ‘supply chain reshaping’. In 2024, decoupling between DMs and EMs is to become a new market-defining feature. Today, the US’s bu
The 42nd JP Morgan Healthcare Conference is set to take place from Jan. 8 to 11 in San Francisco, California, in the U.S. This annual event, held every January, is renowned as the world’s largest healthcare investment venue where major global pharmaceutical companies, emerging biotech firms, and pro
The author is an analyst for NH Investment & Securities. He can be reached at bk@nhqv.com -- Ed.In 2023, an inflection point for the stock market was reached reflecting the differing stances taken by the Fed and market participants. Recently, the Fed has begun looking ahead toward lowering interest
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.With MARIPOSA trials displaying a significant improvement in OS, J&J expects the amivantamab+lazertinib combo to become a standard of care. The firm will file for FDA approval in 2023, and strive to
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.When will global bio indices bottom out? Even if the rankings of the two largest pharmas have changed amid robust sales growth, the S&P500 Healthcare Index has continued to slide this year. We view t
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.The MARIPOSA study has proven the feasibility of lazertinib+amivantamab as a standard first-line treatment. Competing trial FLAURA2 is expected to underperform in terms of OS. In addition, ESMO clini
Yuhan Pharmaceuticals’ lung cancer drug Leclaza has demonstrated enhanced efficacy when combined with Johnson & Johnson’s (J&J) lung cancer treatment. Detailed data is set to be presented at a global conference on Oct. 23, heightening market anticipation.According to industry sources on Oct. 4, Yuha
The author is an analyst for NH Investment & Securities. He can be reached at kyuha.lee@nhqv.com -- Ed.Phase III MARIPOSA meets primary endpointJanssen announced positive topline results from the pivotal phase III MARIPOSA study evaluating Rybrevant (amivantamab) in combination with lazertinib, a th
The author is an analyst for NH Investment & Securities. He can be reached at seungyeon.han@nhqv.com -- Ed.On Sep 26, the share price of HanAll Biopharma partner Immunovant jumped by over 97% on surprise interim data from the IMVT-1402 phase I trial. Encouraging results were reported in terms of bot
Yuhan Corp. announced that it will collaborate with Cyrus Therapeutics, a biopharmaceutical company with targeted proteolysis development technology, to jointly develop new anti-cancer drugs and candidates.The two companies will conduct basic research on anti-cancer drug development, the joint devel
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.Yuhan posted 2Q23 consolidated OP of W27.1bn, significantly beating consensus. Earnings should continue to improve on: 1) the likely listing of Lazertinib as a first-line treatment for NSCLC in Korea
The trend of collaborations between domestic and foreign enterprises of various sizes to achieve success in new drug development is on the rise. Such collaborations are viewed within the industry as a potential model for “Korean-style Open Innovation” in the pharmaceutical and biotech sectors.Accord
The author is an analyst for NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.GPM for domestic first-line NSCLC treatment sales is estimated at 62% of GPM for Janssen’s global Lazertinib royalties in 2028. When enrolled in insurance coverage, drug prices tend to fall on a hike
Yuhan Corporation announced on May 30 that it has signed a technology licensing agreement with J INTS BIO for the tyrosine kinase inhibitor (TKI) “JIN-A04” targeting HER2.The total contract size amounts to 429.8 billion won (US$325.8 million), inclusive of an upfront payment of 25 billion won (US$19
The author is an analysts of NH Investment & Securities. He can be reached at pk.park@nhqv.com -- Ed.At Yuhan, 1Q23 non-consolidated and consolidated OP likely came in at respective W14.6bn (beating consensus) and W13.3bn (missing consensus). We anticipate consolidated earnings improvement after com
The author is an analyst of KB Securities. He can be reached at kimtaehee@kbfg.com. -- Ed.Maintain BUY; trim target price (KRW72,000→KRW70,000) We trim our TP (KRW72,000→KRW70,000) on Yuhan to reflect changes to 2023 ERP (5.41%), RFR (3.32%) and earnings estimates following the 4Q22 earnings release
The author is an analyst of NH Investment & Securities. He can be reached at pk.park@nhqv.co. -- Ed. Laser301 data were recently released at the ESMO Asia Congress 2022. Against this backdrop, attention is turning to Janssen’s commercialization strategy for Lazertinib. A competing phase III clinical